

May 3, 2022



Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S.

WOODSTOCK, Ga.--(BUSINESS WIRE)-- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group DMCC, received EPA approval for Nanocyn® as a hospital-grade disinfectant in the United States. Nanocyn®, which is manufactured by Sonoma using its patented Microcyn® Technology, is a ready to use hard-surface disinfectant that may reduce the risk of infection by treating hard, non-porous surfaces, making it especially useful in high-risk areas such as hospitals, schools, mass transit, and care facilities.

Nanocyn® hospital-grade disinfectant is currently sold by MicroSafe Group in Europe, the Middle East/West Africa and Australia. Nanocyn has been proven to kill a variety of bacteria, such as *Staphylococcus aureus* and *Pseudomonas aeruginosa*, and has a 30 second kill time for many viruses, including norovirus, on hard non-porous surfaces. In May 2020, Nanocyn was entered into the Australian Register of Therapeutic Goods (ARTG) for use against SARS-CoV-2 (COVID-19). Nanocyn utilizes Sonoma's patented Microcyn technology which has a long, proven record of significantly reducing numerous bacteria, viruses, fungi and spores on many surfaces. For more information see www.sonomapharma.com/literature/.

The EPA approval process was a coordinated effort by Sonoma and MicroSafe Group. MicroSafe Group managed and financed the regulatory process with the EPA in exchange for non-exclusive rights to distribute Nanocyn in the United States. Sonoma provided expertise and manufactured the required product samples.

"The MicroSafe Group is very pleased with the EPA approval of Nanocyn® hospital-grade disinfectant, known as MicroSafe® disinfectant in Europe, the Middle East/West Africa and Australia. The EPA approval validates over 20 years of research, development and independent testing that determines the unique stability and efficacy of Microcyn® Technology, a revolution in stable HOCl," said Safwan Abdallah, COO of the MicroSafe Group. "Furthermore, Nanocyn®'s extraordinarily low toxicity profile as categorized by the EPA (lowest Category IV per 40 CFR 156.62) means that the product does not have special handling or disposal requirements. These features, in combination with its impressive kill time of viruses on treated hard non-porous surfaces, may make it a game changer in the realm of infection control," Safwan continued.

“We are excited to bring our successful partnership with MicroSafe Group to the United States,” said Amy Trombly, CEO of Sonoma. “We believe Nanocyn® hospital-grade disinfectant has countless applications due to its efficacy and safety profile, and we are eager to play a role to help curb the spread of infectious disease here in the United States and globally.”

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company has offices in Woodstock, Georgia, and Boulder, Colorado, as well as manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.

About MicroSafe Group

The MicroSafe Group has operations internationally with its head office in Dubai, United Arab Emirates. With regional offices in the Middle East, as well as MicroSafe Care Australia and Canada, MicroSafe Group is providing innovative solutions to a wide range of industries and healthcare providers. The MicroSafe Group promotes only products it believes will truly revolutionize healthcare – products that will enrich the lives of patients and healthcare professionals all over the world. Interested distributors for Europe, West Asia and North Africa may contact Safwan Abdallah, COO of MicroSafe Group at info@microsafecare.com. For Australia please contact MicroSafe Australia’s Managing Director Matt Seifert, at info@microsafe.com.au. More information can be found at www.microsafe.com and www.microsafe.com.au.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “expect,” “promise,” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks resulting from the global COVID-19 pandemic, that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual

patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development and clinical studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20220503005592/en/>

Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.

ir@sonomapharma.com

Source: Sonoma Pharmaceuticals, Inc.